EMA Thumbs Up For HyQvia As Maintenance Therapy For Rare Neurological Disorder

The European Medicines Agency has recommended in favor of allowing new uses of four already-approved drugs and suspending the marketing authorization of several generics tested by an Indian-based CRO. 

Businessman showing thumbs up - closeup shot
Four EU Medicines Are On Track For Labeling Changes Following Positive CHMP Opinions • Source: Shutterstock

Takeda/Baxalta Innovations’ immune globulin (IG) treatment HyQvia (human normal immunoglobulin) is on track to secure a new EU-wide indication as maintenance therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

HyQvia is already approved in the EU as a replacement therapy in adults, children and adolescents with primary immunodeficiency (PI)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography